Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Pro Medicus Shares Edge Up 0.49% as Company Invites Investors to 2026 AGM on 25 November
Highlights:
Pro Medicus Limited (ASX: PME) issued its Notice of Annual General Meeting on 23 October 2026, setting out the schedule, resolutions and participation arrangements for this year’s shareholder gathering. Market data showed the shares last priced at AU$194.360, up AU$0.940, or 0.485%, on the day.
Meeting Format and Venue
The AGM will start at 10:00am AEDT on 25 November 2026. Investors can attend in person at Leonda By The Yarra in Hawthorn, Victoria, or take part online through the company’s webcast portal. A web phone option is also offered for those who prefer to speak their questions aloud. Voting is not possible by web phone. Every resolution will be decided by poll. Only people registered as shareholders at 7:00pm AEDT on Monday, 23 November 2026 will be entitled to vote.
Items Put Forward for Voting
Shareholders will be presented with the annual financial statements, directors’ report and auditor’s report for the financial year ended 30 June 2026. They will then consider an advisory vote on the Remuneration Report, which does not bind the board. Four directors will face a vote. Ms Deena Shiff, Dr Leigh Farrell and Mr Anthony Hall are up for re-election, while Mr Timothy Reed, appointed on 1 October 2026, seeks election for the first time. The board has endorsed all nominees and recommended that shareholders support their respective appointments.
The final item asks shareholders to approve securities issues under the amended Long-Term Incentive Plan. The company said material changes to the plan mean the approval granted at the 2024 AGM no longer applies. The updates include alignment with employee share scheme rules in the Corporations Act, broader malus and clawback provisions, tighter restrictions on hedging unvested securities and wider board powers. The cap stays at 10,000,000 securities, and since the 2024 approval the company has issued 88,165 performance rights.
Voting Procedures and Shareholder Questions
Shareholders may submit proxy appointments through the share registry’s online platform or via post, fax, hand delivery, or the QR code provided on the proxy form. The Chair intends to cast all undirected proxy votes in support of each resolution.
Questions can be lodged in advance through the registry website or submitted live during the meeting. Individual replies will not be sent, but the chair and chief executive will address common themes.
Conclusion
The 23 October 2026 notice gives investors the information needed to prepare for the AGM. Shareholders are encouraged to review the 2026 Annual Report and the Notice of Meeting on the company’s investor website before casting their votes.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au